| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| WB Predicted band size | 104 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human GANC |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是基于假设“GANC抗体”指代胃腺癌(Gastric Adenocarcinoma)相关抗体的模拟参考文献示例。请注意，这些文献为虚构示例，仅用于演示格式：
---
1. **文献名称**：*Novel GANC-Specific Monoclonal Antibodies for Targeted Therapy in Gastric Cancer*
**作者**：Zhang, L. et al.
**摘要**：该研究开发了针对胃腺癌细胞表面抗原GANC的单克隆抗体，体外实验显示其可特异性结合肿瘤细胞并抑制增殖，为靶向治疗提供新策略。
2. **文献名称**：*Diagnostic Utility of Anti-GANC Antibodies in Early-Stage Gastric Adenocarcinoma*
**作者**：Tanaka, H. et al.
**摘要**：通过ELISA检测患者血清中的抗GANC抗体，发现其敏感性和特异性均优于传统标志物(如CEA)，提示其作为早期诊断工具的潜力。
3. **文献名称**：*GANC Antibody-Drug Conjugates: Efficacy and Safety in Preclinical Models*
**作者**：Wang, Y. & Patel, S.
**摘要**：研究构建了GANC抗体-药物偶联物(ADC)，在动物模型中显著缩小肿瘤体积且毒性可控，支持进一步临床转化研究。
4. **文献名称**：*Autoimmune Implications of Anti-GANC Antibodies in Paraneoplastic Syndromes*
**作者**：Müller, R. et al.
**摘要**：探讨了胃腺癌患者中抗GANC抗体与副肿瘤性神经系统综合征的关联，揭示其可能通过分子模拟机制诱发自身免疫反应。
---
**备注**：若“GANC抗体”指其他特定靶点(如基因或蛋白缩写)，建议提供更多背景信息或确认术语准确性，以便检索更相关的文献。
GANC antibodies, targeting ganciclovir, are immune responses that may develop in patients undergoing long-term ganciclovir therapy, particularly in immunocompromised individuals such as transplant recipients or those with HIV/AIDS. Ganciclovir, a nucleoside analog, is widely used to treat cytomegalovirus (CMV) infections. However, prolonged exposure can trigger the production of anti-drug antibodies (ADAs), including GANC antibodies, through adaptive immune activation. These antibodies may neutralize the drug, reducing its bioavailability and therapeutic efficacy, potentially leading to treatment failure or viral resistance.
The emergence of GANC antibodies highlights challenges in managing chronic viral infections requiring extended antiviral regimens. While ADA development is less common with ganciclovir compared to biologic therapies, its clinical significance remains understudied. Risk factors include high-dose regimens, intermittent dosing, and genetic predispositions. Monitoring antibody titers and viral load is crucial in refractory CMV cases to guide therapeutic adjustments, such as switching to alternative antivirals (e.g., foscarnet or letermovir) or optimizing immunosuppression. Further research is needed to clarify the prevalence, kinetics, and clinical impact of GANC antibodies to refine personalized treatment strategies.
×
